Siglec-6 inhibitors as a chemical class are characterized by their ability to modulate the activity of the Siglec-6 protein, which is a sialic acid-binding immunoglobulin-type lectin. This protein typically recognizes sialylated carbohydrates and can transduce signals that influence a variety of cellular processes. The inhibitors listed above are not exclusively selective for Siglec-6 but can impact the function of this protein indirectly through interference with related pathways or cellular mechanisms. These compounds can exert their effects by altering the phosphorylation status of proteins downstream of Siglec-6, disrupting the carbohydrate recognition and binding functions of Siglec-6, or affecting other molecular signalling events and cellular conditions that are necessary for the optimal function of Siglec-6.
The inhibition of Siglec-6 can occur through various mechanisms, such as the direct competition for ligand binding, alteration of the cellular localization and distribution of the protein, or interference with the downstream signaling pathways. Chemicals such as tyrosine kinase inhibitors can affect the phosphorylation events that are critical for Siglec-6 signaling. On the other hand, fucose analogs and sialic acid derivatives can directly compete with the binding of natural ligands to the carbohydrate recognition domain of Siglec-6, resulting in altered signaling. Other inhibitors can influence the protein's activity by modulating intracellular conditions, such as calcium levels, cAMP levels, and the integrity of the cytoskeleton, which are all important for the proper functioning of Siglec-6. Additionally, macroscopic cellular responses, including action potentials and lysosomal functions, can also impact the signaling abilities of Siglec-6.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
A tyrosine kinase inhibitor that can interfere with the intracellular signaling cascades, possibly affecting the Siglec-6-associated pathways. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A fucose analog that can competitively inhibit the binding of fucose-containing ligands to Siglec-6, thereby modulating its function. | ||||||
N-Acetylneuraminic acid | 131-48-6 | sc-281055A sc-281055 sc-281055D sc-281055B sc-281055C | 1 g 5 g 25 g 100 g 250 g | $82.00 $153.00 $320.00 $572.00 $1336.00 | ||
A sialic acid derivative that can compete with natural sialic acid ligands for Siglec-6 binding, modifying its activity. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
An actin polymerization inhibitor that can disrupt cytoskeletal arrangements, potentially affecting Siglec-6's cellular distribution and signaling. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
A calcium channel blocker that can alter intracellular Ca2+ levels, influencing Siglec-6 signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can affect the PI3K/Akt pathway, which can intersect with and modulate Siglec-6 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An inhibitor of MEK, a part of the MAPK pathway, that can alter the functional outcomes of Siglec-6 engagement. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
An adenylyl cyclase activator that increases cAMP levels, potentially affecting Siglec-6-associated cellular signaling. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
An NF-κB pathway inhibitor that can modulate the transcriptional activity of genes, possibly affecting Siglec-6 signaling. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
A non-selective beta-adrenergic receptor blocker that can influence GPCR signaling, which can affect pathways that Siglec-6 is involved in. | ||||||